Reduced-Fluence Photodynamic Therapy Combined With Intravitreal Bevacizumab for Polypoidal Choroidal Vasculopathy

Title
Reduced-Fluence Photodynamic Therapy Combined With Intravitreal Bevacizumab for Polypoidal Choroidal Vasculopathy
Author(s)
장우혁임수호[임수호]사공민
Keywords
EPITHELIUM-DERIVED FACTOR; ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; CLINICAL CHARACTERISTICS; JAPANESE PATIENTS; HUMAN EYES; NEOVASCULARIZATION; VERTEPORFIN; RANIBIZUMAB; EXPRESSION
Issue Date
201205
Publisher
ELSEVIER SCIENCE INC
Citation
AMERICAN JOURNAL OF OPHTHALMOLOGY, v.153, no.5, pp.873 - 882
Abstract
PURPOSE: To evaluate the efficacy and safety of reduced-fluence photodynamic therapy (PDT) combined with bevacizumab for polypoidal choroidal vasculopathy (PCV). DESIGN: Prospective, noncomparative, interventional case series. METHODS: Sixteen treatment-naive patients with polypoidal choroidal vasculopathy were treated with reduced-fluence PDT combined with bevacizumab. All patients were followed up monthly for 12 months with measurements of best-corrected visual acuity (BCVA) and central foveal thickness by optical coherence tomography. Indocyanine green angiography and fluorescein angiography were performed every 3 months. Patients were re-treated with reduced-fluence PDT combined with bevacizumab or with sole injection of bevacizumab when indicated. RESULTS: The mean logMAR BCVA showed significant improvement from 0.76 at baseline to 0.46 at 12 months (P = .002). At 12 months, the BCVA improved in 9 eyes (56.3%) by 3 lines or more, was stable in 6 eyes (37.5%), and decreased in 1 eye (6.3%) because of recurrence of polyps. During the study period, 3 patients (18.8%) had recurrence of polyps and 2 patients (12.5%) had persistent polyps. Mean episodes of reduced-fluence PDT and mean injections of intravitreal bevacizumab over 12 months were 1.44 and 2.44, respectively. Although 3 patients had mild choroidal non-perfusion-1 eye after 1 session of PDT and 2 eyes after 2 sessions no severe complications, including endophthalmitis, uveitis, or subretinal hemorrhage, developed. CONCLUSION: Reduced-fluence PDT combined with bevacizumab for PCV seemed to be effective for improving vision and reducing complications. Further study to optimize the light dose of PDT in combination therapy is needed in order to achieve better treatment outcomes for PCV. (Am J Ophthalmol 2012;153:873-882. (C) 2012 by Elsevier Inc. All rights reserved.)
URI
http://hdl.handle.net/YU.REPOSITORY/28412http://dx.doi.org/10.1016/j.ajo.2011.09.031
ISSN
0002-9394
Appears in Collections:
의과대학 > 안과학교실 > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE